β1 整合素预测乳腺癌的生存：临床病理和免疫组织化学研究。
Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.
机构信息
Department of Pathology, Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Avenida Professor Moraes Rêgo S/N, 50670-901, Recife, Pernambuco, Brazil.
出版信息
Diagn Pathol. 2012 Aug 16;7:104. doi: 10.1186/1746-1596-7-104.
BACKGROUND
The main focus of several studies concerned with cancer progression and metastasis is to analyze the mechanisms that allow cancer cells to interact and quickly adapt with their environment. Integrins, a family of transmembrane glycoproteins, play a major role in invasive and metastatic processes. Integrins are involved in cell adhesion in both cell-extracellular matrix and cell-cell interactions, and particularly, β1 integrin is involved in proliferation and differentiation of cells in the development of epithelial tissues. This work aimed to investigate the putative role of β1 integrin expression on survival and metastasis in patients with breast invasive ductal carcinoma (IDC). In addition, we compared the expression of β1 integrin in patients with ductal carcinoma in situ (DCIS).
METHODS
Through tissue microarray (TMA) slides containing 225 samples of IDC and 67 samples of DCIS, β1 integrin expression was related with several immunohistochemical markers and clinicopathologic features of prognostic significance.
RESULTS
β1 integrin was overexpressed in 32.8% of IDC. In IDC, β1 integrin was related with HER-2 (p = 0.019) and VEGF (p = 0.011) expression and it had a significant relationship with metastasis and death (p = 0.001 and p = 0.05, respectively). Kaplan-Meier survival analysis showed that the overexpression of this protein is very significant (p = 0.002) in specific survival (number of months between diagnosis and death caused by the disease). There were no correlation between IDC and DCIS (p = 0.559) regarding β1 integrin expression.
CONCLUSIONS
Considering that the expression of β1 integrin in breast cancer remains controversial, specially its relation with survival of patients, our findings provide further evidence that β1 integrin can be a marker of poor prognosis in breast cancer.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6652215267393871.
背景
多项研究主要集中在癌症的进展和转移上，旨在分析允许癌细胞与其环境相互作用并迅速适应的机制。整合素是一组跨膜糖蛋白，在侵袭和转移过程中起着重要作用。整合素参与细胞与细胞外基质和细胞-细胞相互作用的粘附，特别是β1 整合素参与上皮组织发育中细胞的增殖和分化。本工作旨在研究β1 整合素表达在乳腺浸润性导管癌 (IDC) 患者中的生存和转移中的可能作用。此外，我们比较了原位导管癌 (DCIS) 患者中β1 整合素的表达。
方法
通过包含 225 例 IDC 样本和 67 例 DCIS 样本的组织微阵列 (TMA) 载玻片，β1 整合素的表达与几种免疫组织化学标志物和具有预后意义的临床病理特征相关。
结果
32.8%的 IDC 中β1 整合素过度表达。在 IDC 中，β1 整合素与 HER-2（p=0.019）和 VEGF（p=0.011）的表达有关，并且与转移和死亡有显著关系（p=0.001 和 p=0.05）。Kaplan-Meier 生存分析表明，该蛋白的过度表达在特定生存（诊断和疾病引起的死亡之间的月数）中非常显著（p=0.002）。IDC 和 DCIS 之间（p=0.559）关于β1 整合素的表达没有相关性。
结论
考虑到β1 整合素在乳腺癌中的表达仍然存在争议，特别是其与患者生存的关系，我们的发现进一步证明β1 整合素可以作为乳腺癌预后不良的标志物。
Zotero 插件